BioPorto A/S (DK0011048619) — research page
DK · dk-cm-kg/XCSE/DK0011048619 · as of 2026-11-06
Identity and listing
The issuer is BioPorto A/S, listed on Nasdaq Copenhagen, with ticker DK0011048619, ISIN DK0011048619 and LEI 5299004SWFL5JAN4W830. Security type, segment, sector and jurisdiction are not on the record. Listing status is listed, not halted.
| field | value | source · read date |
|---|---|---|
| name | BioPorto A/S | source · 2026-11-06 |
| exchange | Nasdaq Copenhagen | source · 2026-11-06 |
| ticker | DK0011048619 | source · 2026-11-06 |
| ISIN | DK0011048619 | source · 2026-11-06 |
| LEI | 5299004SWFL5JAN4W830 | source · 2026-11-09 |
| security type | not on the record | |
| segment | not on the record | |
| sector | not on the record | |
| jurisdiction | not on the record | |
| status | listed, not halted | source · 2026-11-09 |
The disclosure read
The record holds 21 filings across 18 filing days in the twelve months to 2026-11-06. The median gap between filing days is 8 days. The latest filing is dated 2026-09-28, is of type Investor News, and is 39 days before the record date. The median gap for Nasdaq Copenhagen is 8.0 days, the median filings per issuer is 25, and the median latency is 4.0 days; the sector median is not on the record.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 21 | 8 | 39 |
| exchange median: Nasdaq Copenhagen (119 issuers) | 25 | 8 | 4 |
| date | type | category | filing |
|---|---|---|---|
| 2026-09-28 | Investor News | Investor News | Unlocking the Growth - Invitation to BioPorto's investor meeting on October 7 |
| 2026-08-20 | Half Year financial report | Half Year financial report | BioPorto announces Interim Results for the Second Quarter and First half of 2026 |
| 2026-06-15 | Other information disclosed according to the rules of the Exchange | Other information disclosed according to the rules of the Exchange | Grant of Warrants |
| 2026-06-09 | Inside information | Inside information | BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback |
| 2026-05-21 | Interim report (Q1 and Q3) | Interim report (Q1 and Q3) | BioPorto announces Interim Result for the First Quarter of 2026 |
window 2025-11-06 to 2026-11-06 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor of record and its location are not on the record. Auditor changes are not on the record, as this market's register has no lifecycle type map yet.
Events and halts
Listing, delisting, name change, domicile change and segment move are not on the record, as this market's register has no lifecycle type map yet. The halt flag is not set; the issuer is listed, not halted.
Orderability
The outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/dk/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.
rule acm-68000/dk/mifid-ii-product-governance/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
The issuer's investor-relations page names 3 research houses: DNB Carnegie, HC Andersen Capital and H.C. Wainwright & Co.
| research house | analyst | source · read date |
|---|---|---|
| DNB Carnegie | Oliver Røst Benneballe | issuer page · 2026-11-12 |
| HC Andersen Capital | Michael Friis | issuer page · 2026-11-12 |
| H.C. Wainwright & Co. | Yi Chen | issuer page · 2026-11-12 |
Open research
The record holds 2 openly published research notes: H.C. Wainwright & Co. dated 2024-02-23, and HC Andersen Capital dated 2023-11-24.
| date | publisher | note | kind |
|---|---|---|---|
| 2024-02-23 | H.C. Wainwright & Co. | BioPorto A/S (BIOPOR.CO) Rating: Buy | independent |
| 2023-11-24 | HC Andersen Capital | Company Name - Bioporto | issuer-sponsored |
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The vintage is not sealed. No sealed years hold the issuer, no earliest sealed date is on the record for the market, and the live record start is not on the record.
Sources
9 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://firds.esma.europa.eu/firds/ (identity.exchange)
- 10.2
- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)
- 10.3
- https://mcp.dk-cm-kg.ai/events/XCSE/DK0011048619 (the disclosure lines)
- 10.4
- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=exchangeNewsFilterCPH|FirstNorthInformationCPH (the halt flag)
- 10.5
- https://dk.eu-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.6
- https://bioporto.com/investor-relations/analyst/ (coverage)
- 10.7
- https://bioporto.com/wp-content/uploads/2024/02/HCWainright-23022024.pdf (open research)
- 10.8
- https://bioporto.com/wp-content/uploads/2024/02/HCA-Research-Report-on-Bioporto-24.11.23.pdf (open research)
- 10.9
- https://mcp.dk-cm-kg.ai/record/XCSE/DK0011048619 (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"DK0011048619"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:7c21c4fc5f7cee88.